Neuropediatrics or pediatric neurology and (re)habilitation is a branch specialty under pediatrics. The main research areas are epilepsy, headache, perinatal brain injuries, and evaluation of prognosis, developmental neurology, neuro-psychiatric states, cerebral palsy, spina bifida, neuromuscular diseases and tumors in the central nervous system.
The work is primarily focused on investigation and diagnosis of suspected neurological diseases. The research is mainly carried out in close cooperation with neurophysiological, neuroradiological, neurochemical, neuropathological and neurogenetic units.
Intensive international research focused on pediatric oncology has resulted in a dramatic increase in overall survival of pediatric cancer diseases during the past fifty years and today four out of five who are diagnosed will survive. Yet these rare diseases still today account for the main medical cause of death in children aged 1-15 years. Increased understanding of the biology, the molecular regulation and genetics has led to 80% cure of the disease.
The goal of contemporary research is to further improve survival, but also to make the treatment more specific and tolerable for the children. The research of the Pediatric Oncology research group at Uppsala University deals spanning from experimental studies using the latest molecular and genetic methods to behavioral research aiming to help children and families better cope with the demanding treatment.
In general, all pediatric oncology patients will take part in international clinical treatment trials, which are nationally approved by the Ethical review committees in Sweden. Patients’ and parents’ consent are a prerequisite for the clinical trials.